Tactogen is developing ‘a next generation of medicines for mental health’ under the leadership of Matthew Baggott.


The company has not made any concrete announcements. On their LinkedIn page it can be found that they are working on empathogen medicines (MDMA is often classified as such).

In April 2021, Tactogen raised U$1.5 million through early-stage venture capital.

The company has indicated that it’s a public benefit corporation.

“We are a public benefit corporation. We seek to improve and sustain individual and community health, primarily by developing safe, effective, and accessible medicines.”

Company Information

Tactogen Website

December, 2019


B2C Biotech Drug Discovery

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)
This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.


HQ / Office 3790 El Camino Real #510, Palo Alto, CA 94306, USA